Ozempic

Eli Lilly and Co. (NYSE:LLY) has come out on top in a weight loss drug competition in a recent study. The study found that patients on Lilly’s Mounjaro lost more weight than those on Novo Nordisk’s (NYSE:NVO) Ozempic. What Happened: The study, published on the JAMA Internal Medicine...

The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga. “Our view is that in the long term, this is not a two-horse race...

Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry’s, are not worried about the impact of weight-loss drugs on their ice cream business, despite the impending spin-off of their parent company Unilever plc‘s (NYSE:UL) ice cream division. What Happened: The duo, both 73,...

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO). What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug...

Novo Nordisk‘s (NYSE:NVO) weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm. In response to this announcement, the company’s U.S.-listed stock is experiencing a surge of over 2% in pre-market trading on Tuesday...

Novo Nordisk A/S (NYSE:NVO) is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs. What Happened: The Danish pharmaceutical company plans to build a new 1.4 million square foot manufacturing plant near Raleigh, North...

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. But, the biotech company, renowned for its cancer and HIV treatments, has not positioned itself as a contender in this lucrative field. Most recently,...

Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial results were released on Thursday and comes at a time when the weightloss drug market is...

Americans love their pets: could the success of Novo Nordisk A/S (NYSE:NVO) drugs Ozempic and Wegovy and Eli Lilly And Co‘s (NYSE:LLY) Zepbound be a model for similar weight loss drugs in the pet market? What Happened: A recent Bloomberg newsletter outlined several recent developments in the...

U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, Wegovy, and Mounjaro. The Judicial Panel on Multidistrict Litigation appointed Marston to manage over 10,000 personal injury lawsuits. U.S. District...

The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors. What Happened: Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer...

Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on generic versions of Novo...

Krispy Kreme Inc. (NASDAQ:DNUT) is facing a critical juncture as it seeks to overcome market challenges and position itself as a dominant player in the fast-food industry. Despite its current stock price hovering near a 52-week low, several analysts and investors see significant potential for...

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...

ReShape Lifesciences Inc. (NASDAQ:RSLS) was trading over 117% in the pre-market a day after it received the nod from the U.S. Patent And Trademark Office to issue a patent for its obesity treatment. What Happened: ReShape, which offers products and services for managing and treating obesity and...